APA (7th ed.) Citation

A, P., M, T., L, B., C, G., V, H., S, C., . . . C, D. (2024). REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. European journal of cancer (Oxford, England : 1990), 202, 114034. https://doi.org/10.1016/j.ejca.2024.114034

Chicago Style (17th ed.) Citation

A, Picca, et al. "REVOLUMAB: A Phase II Trial of Nivolumab in Recurrent IDH Mutant High-grade Gliomas." European Journal of Cancer (Oxford, England : 1990) 202 (2024): 114034. https://doi.org/10.1016/j.ejca.2024.114034.

MLA (9th ed.) Citation

A, Picca, et al. "REVOLUMAB: A Phase II Trial of Nivolumab in Recurrent IDH Mutant High-grade Gliomas." European Journal of Cancer (Oxford, England : 1990), vol. 202, 2024, p. 114034, https://doi.org/10.1016/j.ejca.2024.114034.